GTC
BOLD

Ghost Tree Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

Ghost Tree Capital’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-175,000
Closed -$6.83M – 53
2019
Q1 		$6.83M Sell
175,000
-125,000
-42% -$3.58M 1.78% 22
2018
Q4 		$6.4M Buy
+300,000
New +$7.74M 2.32% 16
2018
Q3 		– Sell
-125,000
Closed -$4.78M – 66
2018
Q2 		$4.78M Buy
+125,000
New +$4.63M 1.41% 26
2017
Q3 		– Sell
-50,000
Closed -$957K – 87
2017
Q2 		$957K Buy
+50,000
New +$799K 0.2% 65

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ghost Tree Capital's BOLD Position: Q2 2019 in Review

Ghost Tree Capital sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2019, closing a stake of 175,000 shares — an estimated $6.83M sold.

Ghost Tree Capital first reported a position in BOLD in Q2 2017 and held it in 4 quarters. The position peaked at $6.83M in Q1 2019. 147 funds tracked by Wall St. Rank hold BOLD as of Q2 2019.

  • Ghost Tree Capital reported no remaining Audentes Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Ghost Tree Capital sold 175,000 Audentes Therapeutics, Inc shares in Q2 2019, an estimated $6.83M.
  • Ghost Tree Capital first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 4 quarters.
  • Ghost Tree Capital's Audentes Therapeutics, Inc position peaked at $6.83M in Q1 2019.
  • 147 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2019.

Based on Ghost Tree Capital's 13F filing for Q2 2019, filed 14 Aug 2019.